Part,  Chapter, Paragraph

  1   II,     4.  3        |                    Robine, J.-M. and J.-P. Michel (2004): Looking
  2   II,     5.  2.  6    |         Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash
  3   II,     5.  2.  7    |                 Allender S, Scarborough P, Peto V and Rayner M (2008):
  4   II,     5.  2.  7    |               LL, Garside DB, Greenland P, Manheim LM, Dyer AR, Wang
  5   II,     5.  2.  7    |                J 28: 2375-414~Greenland P, Knoll MD, Stamler J,. Neaton
  6   II,     5.  2.  7    |                 G, Ferrario M, Chiodini P, Sega R, and Stamler J (
  7   II,     5.  2.  7    |     Donfrancesco C, Vanuzzo D, Chiodini P, Cesana G, Ferrario M, Mattiello
  8   II,     5.  2.  7    |         Cardiovasc Dis 18: S1-16.~Puska P, Vartiainen E, Tuomilehto
  9   II,     5.  2.  7    |                H, Ruokokoski E, Amouyel P (1999): Contribution of
 10   II,     5.  2.  7    |                McQueen M, Budaj A, Pais P, Varigo J, Lisheng A (2004):
 11   II,     5.  3.  9    |         Oncology 8 (9):773-783.~ ~Boyle P, Autier P, Bartelink H,
 12   II,     5.  3.  9    |              773-783.~ ~Boyle P, Autier P, Bartelink H, et al (2003):
 13   II,     5.  3.  9    |               2008).~ ~Ferlay J, Autier P, Boniol M, Heanue M, Colombet
 14   II,     5.  3.  9    |             Heanue M, Colombet M, Boyle P (2007): Estimates of the
 15   II,     5.  3.  9    |        Capocaccia R, Stiller C, Kaatsch P, Berrino F, Terenziani M,
 16   II,     5.  3.  9    |                Issues.~ ~Key T, Appleby P, Barnes I, Reeves G, Endogenous
 17   II,     5.  3.  9    |                iii7.~ ~Micheli A, Baili P, Quinn M, Mugno E, Capocaccia
 18   II,     5.  3.  9    |                Capocaccia R, Grosclaude P, and the EUROCARE Working
 19   II,     5.  3.  9    |             Mugno E, Coebergh JW, Baili P, Verdecchia A, Berrino F,
 20   II,     5.  3.  9    |                Bray F, Ferlay J, Pisani P (2005): Global cancer statistics,
 21   II,     5.  3.  9    |                 Bielska Lasota M, Carli P, Faivre J, Grosclaude P,
 22   II,     5.  3.  9    |                 P, Faivre J, Grosclaude P, Hédelin G, Matsuda T, Moller
 23   II,     5.  3.  9    |                  Santaquilani M, Roazzi P, Lisi D, EUROCARE Working
 24   II,     5.  3.  9    |                    Stewart BW, Kleihues P (2003): World Cancer Report.
 25   II,     5.  4.  8    |              1995 Mar;12(3):271-6~Beck, P, Battlogg, K, Gfrerer, R,
 26   II,     5.  4.  8    |                 R, Trajanoski, Z, Wach, P, and Pieber, T. (2001) Internet
 27   II,     5.  4.  8    |                  Kristensen JK, Ottosen P, Borch-Johnsen K (2008);
 28   II,     5.  5.Int(9) |                                 Gabriel P and Liimatainen M-R (2000):
 29   II,     5.  5.Int(11)|                 Sen. G., A. George, and P. Östlin (eds.) Engendering
 30   II,     5.  5.Int(12)|        differences in mental health. In P. Östlin, M. Danielsson,
 31   II,     5.  5.Int(15)|                 AW, Dewey ME, Delespaul P, Fuhrer R, Hooijer C, Lawlor
 32   II,     5.  5.  1    |               change estimated at -6.1%(P<0.0001), –5.4%(P<0.0001)
 33   II,     5.  5.  1    |               at -6.1%(P<0.0001), –5.4%(P<0.0001) and –5.0%(P<0.0001)
 34   II,     5.  5.  1    |                5.4%(P<0.0001) and –5.0%(P<0.0001) respectively.~ ~
 35   II,     5.  5.  3    |    Dallongeville J, Gilbert CC, Bergman P, Widhalm K, Manios Y, Breidenasse
 36   II,     5.  5.  3    |                12:18-23.~Andlin-Sobocki P, Jönsson B, Wittchen HU,
 37   II,     5.  5.  3    |            Suppl 1:1-27.~Andlin-Sobocki P, Rössler W (2002):Health
 38   II,     5.  5.  3    |                7):155-8.~Andlin-Sobocki P, & Rössler W (2005):Cost
 39   II,     5.  5.  3    |              Baumann A, Zäske H, Decker P, Klosterkötter J, Maier
 40   II,     5.  5.  3    |                 de Girolamo G, Morosini P, Polidori G, Kikkawa T,
 41   II,     5.  5.  3    |                 Jané-Llopis E, Anderson P eds.).~Fang H, Rizzo JA (
 42   II,     5.  5.  3    |        Klosterkötter J, Maier W, Decker P, Möller HJ. (2007): Evaluation
 43   II,     5.  5.  3    |            Harris M, Tranter R, Gutting P, Austin R, Jones-Edwards
 44   II,     5.  5.  3    |                 Lange W, Munk-Jørgensen P, Bertelsen A, Schürmann
 45   II,     5.  5.  3    |               Lysaker PH, Tsai J, Yanos P, Roe D (2007): Associations
 46   II,     5.  5.  3    |               53.~Pilling S, Bebbington P, Kuipers E, Garety P, Geddes
 47   II,     5.  5.  3    |         Bebbington P, Kuipers E, Garety P, Geddes J, Orbach G, Morgan
 48   II,     5.  5.  3    |                 Wahlbeck K), Section B, p. 257-333, 2007.~htt df~Vauth
 49   II,     5.  5.  3    |                Questionnaire and GP and P inquiry/MR review? ~155/
 50   II,     5.  5.  3    |               years MR = Medical record P = Pediatricians ~ = 6-16
 51   II,     5.  5.  3    |           epilepsy and 75% in controls (p<0.0001). The cumulative
 52   II,     5.  5.  3    |                27 and 17% respectively (p<0.0001). Illnesses and accidents
 53   II,     5.  5.  3    |              Oxford, Blackwell Science; p. 50-63.~Beghi E, Sander
 54   II,     5.  5.  3    |              Oxford, Blackwell Science; p. 21-42.~Forsgren L, Beghi
 55   II,     5.  5.  3    |           Gallitto G, Serra S, La Spina P, et al (2005): Prevalence
 56   II,     5.  5.  3    |          Epilepsia 45:1405-1415.~Jallon P (2004): Mortality in patients
 57   II,     5.  5.  3    |                1030.~Loiseau J, Loiseau P, Guyot M, et al (1990):
 58   II,     5.  5.  3    |            Loiseau J, Picot MC, Loiseau P (1999): Short-term mortality
 59   II,     5.  5.  3    |               Nashef L, Walker F, Allen P, et al (1996): Apnoea and
 60   II,     5.  5.  3    |                  Olafsson E, Ludvigsson P, Gudmundsson G, et al (2005):
 61   II,     5.  5.  3    |                 37:1051-1059.~Pazzaglia P, Frank-Pazzaglia L (1976):
 62   II,     5.  5.  3    |             1790-1791.~Rutter M, Graham P, Yule W (1970): A neuropsychiatric
 63   II,     5.  5.  3    |              Boca Raton, FL: CRC Press; p. 239-148.~Tomson T, Beghi
 64   II,     5.  5.  3    |                  Kesselring J, Ketelaer P, Thompson A et al; (2004):
 65   II,     5.  5.  3    |       Confavreux C, Vukusic S, Adeleine P (2003): Early clinical predictors
 66   II,     5.  5.  3    |                 Darmstadt.~Flachenecker P, Zettl UK , Götze U, et
 67   II,     5.  5.  3    |                 in German]~Flachenecker P, Zettl UK, Elias WG, et
 68   II,     5.  5.  3    |                 294.~Henze T, Rieckman, P and Toyka KY (2006): Symptomatic
 69   II,     5.  5.  3    |            Hungarica 13:47-48.~Jedlicka P (1989): Epidemiology of
 70   II,     5.  5.  3    | Leuchtturm-Verlag/LTV Press, Darmstadt, p 294.~Krupp LB, Alvarez LA,
 71   II,     5.  5.  3    |               1985;38(2):203-10.~Lensky P (1994): Geographic disproportion
 72   II,     5.  5.  3    |          consensus group) and Rieckmann P (2006): Escalating immunomodulatory
 73   II,     5.  5.  3    |            Amsterdam.~Ranzato F, Perini P, Tzintzeva E et al (2003):
 74   II,     5.  5.  3    |             Scand 110: 331336.~Sobocki P, Pugliatti M, Lauer L, Kobelt
 75   II,     5.  5.  3    |          Psychiatry 74:25-28.~Sundström P, Nyström L, Forsgren L (
 76   II,     5.  5.  3    |            Scand 103:214-218.~Sundström P, Nyström L, Forsgren L (
 77   II,     5.  5.  3    |          Psychiatry 74:29-32.~Sundström P, Svenningsson A, Nyström
 78   II,     5.  5.  3    |                 at http f]~Van Ooteghem P, De Hooghe MB, Vlietnick
 79   II,     5.  5.  3    |                1):21-27.~Andlin-Sobocki P, Jonsson B, Wittchen HU,
 80   II,     5.  5.  3    |                Carlo A, Rocca WA, Vanni P, Maggi S, Perissinotto E,
 81   II,     5.  5.  3    |                 Monetti VC, De Bastiani P (1991): Parkinson’s disease
 82   II,     5.  5.  3    |                 G, Friedman A, Kanovsky P, Larsen JP, Lees A, Oertel
 83   II,     5.  5.  3    | Pharmacoeconomics 16(1):59-69.~Lindgren P, von Campenhausen S, Spottke
 84   II,     5.  5.  3    |               113(9):1234-1238.~McCrone P, Allcock LM, Burn DJ (2007):
 85   II,     5.  5.  3    |                W, Reichmann H, Riederer P, Trenkwalder C, Dodel R,
 86   II,     5.  5.  3    |           Aiello I, Tola R, De Bastiani P, Pirisi A, Devoto MC (1980):
 87   II,     5.  6.  6    |                 13~Bergman S, Herrstrom P, Hogstrom K, Petersson IF,
 88   II,     5.  6.  6    |          Breedveld F, Dougados M, Emery P, Ferraccioli G, Hazes JM,
 89   II,     5.  6.  6    |                 Metab 314:224-229~Croft P, Coggon D, Cruddas M, Cooper
 90   II,     5.  6.  6    |                 1709~Hakala M, Nieminen P, Koivisto O (1994): More
 91   II,     5.  6.  6    |                Care 16(4):1193-200~Juni P, Dieppe P, Donovan J, Peters
 92   II,     5.  6.  6    |                 1193-200~Juni P, Dieppe P, Donovan J, Peters T, Eachus
 93   II,     5.  6.  6    |          Karaharju EO, Porras M, Luthje P, Jakobsson A (1988): Functional
 94   II,     5.  6.  6    |           Marples G, Chandler C, Dawson P (1999): Prevalence of back,
 95   II,     5.  6.  6    |                  Dreinhofer K, Schrader P, Sturmer T, Puhl W, Gunther
 96   II,     5.  6.  6    |                 adults.~Oleksik A, Lips P, Dawson A, Minshall ME,
 97   II,     5.  6.  6    |                 E, Torrance GW, Tugwell P (1992): Physical disability
 98   II,     5.  6.  6    |                 Turner G, Webb R, Asten P, Barrett E, Lunt M, Scott
 99   II,     5.  7.  7    |          Ejerblad E, Fored CM, Lindblad P, Fryzek J, McLaughlin JK,
100   II,     5.  7.  7    |                  441-8.~Otero A, Gayoso P, Garcia F, de Francisco
101   II,     5.  7.  7    |          S16-S19.~Pontoriero G, Pozzoni P, Vecchio LD, Locatelli F (
102   II,     5.  8.  3    |                glaucoma (RR = 1.3) [all p <0.05].~ ~The Longitudinal
103   II,     5.  8.  5    |                 spirometric parameters (p<0.001). In the second part,
104   II,     5.  8.  6    |                 setting (41% vs. 12.5%, p<0.05) and to receive long-term
105   II,     5.  8.  6    |                 home care (26% vs 9.7%, p<0.05), but were much less
106   II,     5.  8.  6    |                hospital (47.6% vs 5.1%, p<0.001) or at home (37.4%
107   II,     5.  8.  6    |                 at home (37.4% vs 2.8%, p<0.05) than people with lung
108   II,     5.  8.  7    |             Balmes J, Becklake M, Blanc P, Henneberger P, Kreiss K,
109   II,     5.  8.  7    |                 M, Blanc P, Henneberger P, Kreiss K, Mapp C, Milton
110   II,     5.  8.  7    |               Baekke Borgeskov H, Lange P (2007): The cost of treating
111   II,     5.  8.  7    |                 WM, Gillespie S, Burney P, Mannino DM, Menezes AMN,
112   II,     5.  8.  7    |                 C, Gislason T, Vermeire P, Svanes C, Anto JM, Burney
113   II,     5.  8.  7    |               Svanes C, Anto JM, Burney P (2004): European Community
114   II,     5.  8.  7    |                Huchon G, Huas D, Godard P, Voinet C, Chanal I, Jourdanne
115   II,     5.  8.  7    |              Nieminen MM, Aine T, Bakke P, Janson C (2007): Mortality
116   II,     5.  8.  7    |         Johannessen A, Omenaas E, Bakke P, Gulsvik A (2005): Incidence
117   II,     5.  8.  7    |                   Jorgensen NR, Schwarz P, Holme I, Henriksen BM,
118   II,     5.  8.  7    |               879-885.~ ~Lokke A, Lange P, Scharling H, Fabricius
119   II,     5.  8.  7    |                  Scharling H, Fabricius P, Vestbo J (2006): Developing
120   II,     5.  8.  7    |            Stewart A, Lamont C, Roseman P, Didsbury P (2004): A chronic
121   II,     5.  8.  7    |           Lamont C, Roseman P, Didsbury P (2004): A chronic disease
122   II,     5.  8.  7    |             Soriano JB, Maier WC, Egger P, Visick G, Thakrar B, Sykes
123   II,     5.  8.  7    |                  Stratelis G, Jakobsson P, Molstad S, Zetterstrom
124   II,     5.  8.  7    |         Kogevinas M, Kromhout H, Burney P, Antó Jm, and The ECRHS
125   II,     5.  9.  3    |                 women and 49.5% in men, P 001). Asthmatic patients
126   II,     5.  9.  3    |               onset (7.8 vs 15.9 years, P 001) and a shorter duration
127   II,     5.  9.  3    |             disease (5.6 vs 16.1 years, P 001) than patients with
128   II,     5.  9.  3    |                 remission was strongly (P 001) and inversely related
129   II,     5.  9.  3    |                significant correlation (P<0.0001) between the prevalence
130   II,     5.  9.  3    |          remarkable in German children (p <0,05)~ ~The survey by Compalati
131   II,     5.  9.  4    |              for wheeze (1.34 to 0.98:1 P <0.0002), asthma (1.74 to
132   II,     5.  9.  4    |                  asthma (1.74 to 1.02:1 P <0.0001), eczema (1.42:1
133   II,     5.  9.  4    |                eczema (1.42:1 to 0.81:1 P <0.0001) and hay fever (
134   II,     5.  9.  4    |               hay fever (1.46 to 0.93:1 P <0.0001). The diagnosis
135   II,     5.  9.  4    |               risk=1.6, 95% CI 1.1-2.3, P=0.017). Risks were higher
136   II,     5.  9.  4    |                 symptoms (2.4, 1.3-4.6, P=0.008). Among common occupations,
137   II,     5.  9.  4    |              for nursing (2.2, 1.3-4.0, P=0.007). Asthma risk was
138   II,     5.  9.  4    |                RR=3.3, 95% CI 1.0-11.1, P=0.051). The population-attributable
139   II,     5.  9.  4    |               levels of the epitope Dep p 1 of house dust mites (MAS
140   II,     5.  9.  4    |       sensitization to Olea europea and P. judaica is higher in Southern
141   II,     5.  9.  4    |                and 8.0% of the females (P=0.03). Analysis by multiple
142   II,     5.  9.  4    |               the time spent in Apulia (P=0.04 for hay-fever) (Ventura
143   II,     5.  9.  4    |                  and 9.7% respectively, P <0.001; current wheeze:
144   II,     5.  9.  4    |                 and 6.9%, respectively, P = 0.04). Lower risks for
145   II,     5.  9.  7    |           Kogevinas M, Jarvis D, Burney P. (2007a): Nu I. Clin Exp
146   II,     5.  9.  7    |           Janson C, Kogevinas M, Burney P, Jarvis D (2007b): Ge I.
147   II,     5. 10.  7    |                Pumphrey RSH, Stahl Skov P, van Ree R, Vlieg-Boerstra
148   II,     5. 10.  7    |           Anklam E, Baumgartner S, Koch P, Crevel RW, Frewer L (2004):
149   II,     5. 10.  7    |            Mills ENC, Mackie AR, Burney P, Beyer K, Frewer L, Madsen
150   II,     5. 11.  7    |         Venereol 2001;81:193-7.~ ~Boyle P, Dorè JF, Autier P, Ringborg
151   II,     5. 11.  7    |                Boyle P, Dorè JF, Autier P, Ringborg U (2004): Cancer
152   II,     5. 11.  7    |                 2004;15(1):5-6.~ ~Boyle P, Smans M (2003): Cancer
153   II,     5. 11.  7    |                Ferlay J, Bray F, Pisani P, Parkin DM (2001): GLOBOCAN
154   II,     5. 11.  7    |                 G, Obsitnikova A, Boyle P. Trends in the incidence
155   II,     5. 11.  7    |                151(2):446-51.~ ~Verboom P, Hakkaart-van Roijen L,
156   II,     5. 11.  7    |                 L, Coenraads PJ, Elsner P, Grob JJ, Bouwes Bavick
157   II,     5. 12.  7    |                169.~ ~Corrao G, Ferrari P, Zambon A, Torchio P, Arico
158   II,     5. 12.  7    |            Ferrari P, Zambon A, Torchio P, Arico S, Decarli A (1997):
159   II,     5. 12.  7    |                 27:914-919.~ ~D'Argenio P, Esposito D, Mele A, Ortolani
160   II,     5. 12.  7    |             Adamo B, Rapicetta M, Forte P,~Pisani A, Soldo L, Sarrecchia
161   II,     5. 12.  7    |                 Suppl 1:S19-33.~ ~Sauer P, Hansmann J, Richter GM,
162   II,     5. 15.  6    |                 Dear JW, Lilitkarntakul P, Webb DJ (2006): Are rare diseases
163   II,     5. 15.  6    |         Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J (2007):
164   II,     5. 15.  6    |              Wilson DA, Kanavos P, Ubel P, Rovira J (2007): Assessing
165   II,     8.  2.  1    |      Disabilities 18, 295-304.~Kramers, P.G.N., (2003). The ECHI project:
166   II,     8.  2.  1    |            Limited.~Linehan, C., Walsh, P.N., et al., (2007). POMONA
167   II,     8.  2.  1    |                 H., Simpson, N., Patel, P., & Rowe, S. (1998). Reliability
168   II,     8.  2.  1    |             eurpub/13.suppl_1.47~Walsh, P.N., Linehan, C., Kerr, M.,
169   II,     9            |                  Pomerleau et al, 2003: p. 455~ ~Levels of physical activity
170   II,     9.  1.  1    |                  Oury JF, Luton D, Blot P (2002): Differences in management
171   II,     9.  1.  1    |               S45-52.~ ~Cans C, Guillem P, Fauconnier J, Rambaud P,
172   II,     9.  1.  1    |                P, Fauconnier J, Rambaud P, Jouk PS (2003): Disabilities
173   II,     9.  1.  1    |                  Glinianaia SV, Pharoah P, Sturgiss SN (2000): Comparative
174   II,     9.  1.  1    |                  Cnattingius S, Bergsjo P (2002): Registration artifacts
175   II,     9.  1.  1    |         Statistics, 1992.~ ~Van Reempts P, Gortner L, Milligan D,
176   II,     9.  1.  2    |                Stoll C and Mastroiacovo P (2006): "Trends of Selected
177   II,     9.  1.  2    |                Gatt M, de Walle H, Braz P, Latos-Bielenska A, Gener
178   II,     9.  1.  2    |         Genetics 2007; 10:93-6.~De Wals P et al, (2007): Reduction
179   II,     9.  1.  2    |                 C, Garbis H, McElhatton P, Reuvers M, Robert E, Rost
180   II,     9.  1.  2    |          Tonningen M, Scialli A, Peters P (2001): Drugs during pregnancy
181   II,     9.  2.  7    |             Eurobarometer Issue No. 246 p 13. 9 November, 2006~ ~European
182   II,     9.  2.  7    |             accessed 11.06)~ ~Heuveline P., Timberlake J.M. (2000):
183   II,     9.  3.  1    |               distribution” (WHO, 2000, p.6), and with the recognition
184   II,     9.  3.  1    |                 are at ‘specific risk’ (p.35) there are few initiatives
185   II,     9.  3.  1    |                  Pomerleau et al, 2003: p. 455~ ~Levels of physical activity
186   II,     9.  3.  1    |              Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J (2007):
187   II,     9.  3.  1    |               Sen. George GA and Östlin P). MITPress, Cambridge~ ~
188   II,     9.  3.  1    |              Journal of Urology. 84(1): p. 50-56.~ ~Beral V (2003):
189   II,     9.  3.  1    |                 9382; 419-427.~ ~Boyle, P. Robertson, C. Mazzeha,
190   II,     9.  3.  1    |                92. 943 – 947~ ~Branney, P White, AK (2008) Big boys
191   II,     9.  3.  1    |              Impotence Research. 12(6): p. 305-311.~ ~British Heart
192   II,     9.  3.  1    |              Journal of Psychiatry, 39: p. 921 - 931.~ ~De Smedt M (
193   II,     9.  3.  1    |               veille sanitaire, No. 72. p 6~ ~European Agency for
194   II,     9.  3.  1    |                pp. 245-253(9)~ ~Gabriel P, Liimatainen M-R (2000):
195   II,     9.  3.  1    |              Cancer Inst, 1997. 89(20): p. 1516-23~ ~Makino M, Tsuboi
196   II,     9.  3.  1    |             Qaseem, A Snow, V Shekelle, P Hopkins Jr R. Forciea, MA
197   II,     9.  3.  1    |                 Journal of Urology. 90: p. 433-441.~ ~UNAIDS, UNFPA,
198   II,     9.  3.  2    |                  Oury JF, Luton D, Blot P (2002): Differences in management
199   II,     9.  3.  2    |               S45-52.~ ~Cans C, Guillem P, Fauconnier J, Rambaud P,
200   II,     9.  3.  2    |                P, Fauconnier J, Rambaud P, Jouk PS (2003): Disabilities
201   II,     9.  3.  2    |                  Glinianaia SV, Pharoah P, Sturgiss SN (2000): Comparative
202   II,     9.  3.  2    |                  Cnattingius S, Bergsjo P (2002): Registration artifacts
203   II,     9.  3.  2    |                 J, Dekker G, van Dongen P, van Geijn H, Bennebroek
204   II,     9.  3.  2    |             1998;79(1):57-62.~ ~Semenow P (1872) : Compte-rendu général
205   II,     9.  3.  2    |                 M, Foster LB, Hannaford P, Cattaneo A, Olsen J, Bloemenkamp
206   II,     9.  3.  2    |         Statistics, 1992.~ ~Van Reempts P, Gortner L, Milligan D,
207   II,     9.  3.  3    |           Bochow M, Chiarotti F, davies P, Dubois-Arber F, Dür W,
208   II,     9.  3.  3    |            Journal C 271 E , 12/11/2003 P. 0369 - 0374~Facultes Universitaires
209   II,     9.  3.  3    |                their parents. BZgA, 124 p. htt de~Hubert M, Bajos
210   II,     9.  3.  3    |                  UCL Press. London. 442 p.~Imamura M, Tucker J, Hannaford
211   II,     9.  3.  3    |          Imamura M, Tucker J, Hannaford P, da Silva MO, Astin M, Wyness
212   II,     9.  3.  3    |                 Health and Children. 62 p. [http://www.crisispregnancy.
213   II,     9.  3.  3    |              1141-42.~Nikula M, Kaponen P, Haavio-Mannila E, Hemminki
214   II,     9.  3.  3    |               Prev Med 41:247-52.~Weiss,P.(2008) Trends and risk factors
215   II,     9.  3.  3    |          Available at: htt df~Wilkinson P, French R, Kane R, et al (
216   II,     9.  4.  7    |                 Biol Sci Med Sci, (12), p.1277-84.~DECODE study group
217   II,     9.  4.  7    |                  10/2006~ ~Gray A, Fenn P, (1993): Alzheimer’s disease:
218   II,     9.  4.  7    |               Europe.~ ~Jaleel H, Allan P S, Wade A A (1999): Sexually
219   II,     9.  4.  7    |                Health, Volume 13, No. 2 p. 56-61. March 2005~ ~United
220   II,     9.  5.  6    |                 George Sen. G.A, Östlin P). MITPress, Cambridge.~ ~
221   II,     9.  5.  6    |              245~ ~Brodin J, Lindstrand P (2006): Research Report
222   II,     9.  5.  6    |         Perspective.. (Edited by Östlin P, Danielsson M, Diderichsen
223   II,     9.  5.  6    |                Health, Volume 13, No. 2 p. 56-61. March 2005~ ~Wang
224   II,     9.  5.  6    |               of Public Health, 4th ed, p 1596~ ~White AK, Holmes
225  III,    10.  1.  3    |                Oxford University Press; p. 83-87.~Blow FC, Brockmann
226  III,    10.  1.  3    |                Oxford University Press; p. 113-130.~Hart N (2004):
227  III,    10.  1.  3    |                Oxford University Press; p. 89-111.~Jacobs J, Wolin
228  III,    10.  1.  3    |                 and Barlett Publishers; p. 205-8.~Tappy L, Binnert
229  III,    10.  2.  1    |             Control; 12:360-367~ ~Boyle P, Autier P, Bartelink H,
230  III,    10.  2.  1    |               360-367~ ~Boyle P, Autier P, Bartelink H, Baselga J,
231  III,    10.  2.  1    |        Bartelink H, Baselga J, Boffetta P, Burn J, Burns HJG, Christensen
232  III,    10.  2.  1    |                F, McVie JC, Maisonneuve P, Martin-Moreno JM, Newton
233  III,    10.  2.  1    |              Bishop J, Oleari F, Perrin P, Quinn M, Richards M, Ringborg
234  III,    10.  2.  1    |                 C, Neukirch F, Vermeire P, Wjst M and Burney P (2006):
235  III,    10.  2.  1    |           Vermeire P, Wjst M and Burney P (2006): Changes in active
236  III,    10.  2.  1    |             Adami J, Adami H-O, Bofetta P, Nyrén O (2007): Oral use
237  III,    10.  2.  1    |                5. References~ ~Anderson P, Baumberg B (2006): Alcohol
238  III,    10.  2.  1    |           Available at:~htt ~ ~Anderson P, (2007): Commercial Communications
239  III,    10.  2.  1    |                 Blomgren J, Martikainen P, Mäkelä P, Valkonen T, (
240  III,    10.  2.  1    |                J, Martikainen P, Mäkelä P, Valkonen T, (2004): "The
241  III,    10.  2.  1    |               99.~ ~Miller W, Wilbourne P (2002): Mesa Grande: a methodological
242  III,    10.  2.  1    |                C, Lagerlof F, Lingstrom P, Mejare I, Norderam G, Norlund
243  III,    10.  2.  1    |              physical activity. In: Oja P, Borms J., eds. Health-enhancing
244  III,    10.  2.  1    |               116:7-13.~ ~Gordon-Larsen P et al. (2006): Inequality
245  III,    10.  2.  1    |                Central Books.~ ~Hassmen P, Koivula N, Uutela A (2000):
246  III,    10.  2.  1    |                 Duffey K, Gordon-Larsen P (2005): Environmental influences
247  III,    10.  2.  1    |            Health Nutr., 2001, 4, 5(B), p. 1183-1186~Portugal~Data
248  III,    10.  2.  1    |                 OJ C 250 E, 25.10.2007, p. 93White Paper on “A
249  III,    10.  2.  1    |              Journal L 052 , 22/02/2001 P. 0019 – 0025.~http://eur-lex.
250  III,    10.  2.  1    |              Journal L 083 , 22/03/2006 P. 0014 – 0015.~[http://eur-lex.
251  III,    10.  2.  1    |              Journal L 109 , 06/05/2000 P. 0029 – 0042 [http://eur-lex.
252  III,    10.  2.  1    |              Journal L 183 , 12/07/2002 P. 0051 – 0057.~[http://eur-lex.
253  III,    10.  2.  1    |              Journal L 404 , 30/12/2006 P. 00090025 [http://eur-lex.
254  III,    10.  2.  1    |              Journal L 404 , 30/12/2006 P. 0026 – 0038.~[http://eur-lex.
255  III,    10.  2.  1    |                362.~ ~Gallus S, Colombo P, Scarpino V, Zuccaro P,
256  III,    10.  2.  1    |          Colombo P, Scarpino V, Zuccaro P, Negri E, Apolone G, La
257  III,    10.  2.  1    |              World Health Organization; p. 497596.~[ht ] (report
258  III,    10.  2.  1    |          Fernandes T, Mourão I, Moreira P, Rosado V (2004): Prevalence
259  III,    10.  2.  1    |             Rodrigo C, Saavedra Santana P, Peña Quintana L (2003):
260  III,    10.  2.  1    |                Stamatakis E, Primatesta P, Chinn S, Rona R, Falascheti
261  III,    10.  2.  1    |                  Warsaw, Prace IŻŻ 101; p. 444-508 (in Polish).~ ~
262  III,    10.  2.  1    |            Tedstone A, Aviles M, Shetty P, Daniels L (1998): Effectiveness
263  III,    10.  2.  1    |             2000~ ~Hercberg S, Preziosi P, Galan P (2001): Iron deficiency
264  III,    10.  2.  1    |           Hercberg S, Preziosi P, Galan P (2001): Iron deficiency
265  III,    10.  2.  1    |              Bamia C, Karalis D, Vineis P, Palli D, Bueno-de-Mesquita
266  III,    10.  2.  1    |                  Martinez GC, Wallstrom P, Zhang JX, Welch AA, Spencer
267  III,    10.  2.  1    |                Skeie G, Aller A, Amiano P, Berglund G, Nilsson S,
268  III,    10.  2.  1    |                  Haftenberger M, Lagiou P, Kalapothaki V, Evangelista
269  III,    10.  2.  1    |       Dorronsoro Iraeta M, Morote Gomez P, Janzon L, Stattin P, Welch
270  III,    10.  2.  1    |              Gomez P, Janzon L, Stattin P, Welch AA, Spencer EA, Overvad
271  III,    10.  2.  1    |            Klipstein-Grobusch K, Lagiou P, Kalapothaki V, Masala G,
272  III,    10.  2.  1    |       Dorronsoro Iraeta M, Morote Gomez P, Chirlaque MD, Pozo BG,
273  III,    10.  2.  1    |                Welch AA, Lund E, Amiano P, Dorronsoro M, Brustad M,
274  III,    10.  2.  4    |                116.~ ~Brand A, Schröder P, Brand H, Zimmern R (2006):
275  III,    10.  2.  4    |          Mattheisen M, Dahm S, Nürnberg P, Roe C, Johnson J, Cox N
276  III,    10.  2.  4    |                 T F, Schulze J, Schwarz P E, Lindner T H (2007): A
277  III,    10.  2.  4    |       Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J,
278  III,    10.  2.  4    |                    Roberts, R, Sullivan P, Joyce P, Kennedy M (2000):,
279  III,    10.  2.  4    |           Roberts, R, Sullivan P, Joyce P, Kennedy M (2000):, Rapid
280  III,    10.  2.  4    |          Willett E, De Sanjose S, Cocco P, Berndt SI, Brennan P, Brooks-Wilson
281  III,    10.  2.  4    |             Cocco P, Berndt SI, Brennan P, Brooks-Wilson A, Wacholder
282  III,    10.  2.  4    |           Wacholder S, Becker N, Hartge P, Zheng T, Roman E, Holly
283  III,    10.  2.  4    |             Roman E, Holly EA, Boffetta P, Armstrong B, Cozen W, Linet
284  III,    10.  2.  4    |               Bucher C, Kononen J, Haas P, Zuber M, Köchli OR, Mross
285  III,    10.  2.  5    |                  Brubakk AM, Romundstad P, Vik T (2007): Prenatal
286  III,    10.  3.  2    |               in DDT and its metabolite p,p’-DDE, and lesser decreases
287  III,    10.  3.  2    |                DDT and its metabolite p,p’-DDE, and lesser decreases
288  III,    10.  3.  2    |                 Grandjean PJ, Landrigan P (2006): Developmental neurotoxicity
289  III,    10.  3.  2    |          Alimonti, F Petrucci, B Bocca, P Schramel, M Zischka, C Pettersson,
290  III,    10.  4.  1    |             Hurley, F., Pye S., Watkiss P. and Hunt A. (2007) improving
291  III,    10.  4.  2(28)|               EEC (OJ L 187, 16.7.2002, p 30)~
292  III,    10.  4.  2(29)|                 EEC(OJ L 325,12.12.2003 p. 31)~
293  III,    10.  4.  2(30)|                      OJ 121, 29.7.1964, p.1977~
294  III,    10.  4.  2(31)|                    OJ L 224, 18.8.1990, p.19~
295  III,    10.  4.  2(32)|                      OJ 186, 30.6.1989, p.23~
296  III,    10.  4.  2(33)|          Community (OJ L 268, 3.10.1998,p.1)~
297  III,    10.  4.  2(35)|            cereals (OJ L 221, 7.8.1986, p 37).~
298  III,    10.  4.  2(36)|             origin (OJ L 221, 7.8.1986, p 43).~
299  III,    10.  4.  2(37)|        vegetables (OJ L 350,14.12.1986, p 71).~
300  III,    10.  5.  1    |     Vandentorren et al, 2007; Wilkinson P. et al, 2007). Such extreme
301  III,    10.  5.  1    |               Cities. Vol. 23. Issue 5. P. 339352.~Bayerisches Landesamt
302  III,    10.  5.  1    |           Washington: Feb 2003, vol 93, p 288~Said B et al. Outbreaks
303  III,    10.  5.  1    |            Viegi G, Canciani M, Sestini P (2006): La qualità dell’
304  III,    10.  5.  1    |                  6, 583–591;~ ~Wargocki P, Wyon DP (2007): The effects
305  III,    10.  5.  1    |          Available at: htt ~ ~Wilkinson P, et al (2007): Energy, energy
306  III,    10.  5.  3    |                 296-320.~Andlin-Sobocki P, Jönsson B, Wittchen H-U,
307  III,    10.  5.  3    |                 1610-1619.~Martikainen, P. & Valkonen, T. (1996).
308  III,    10.  5.  3    |            Democracy. New York, Harper; p. 82-85.~Thomas T, Secker
309  III,    10.  6.  1    |                Brand RJ, Syme SL, Puska P (1988). Social connections
310   IV,    11.  6.  5    |              Health 12(2): 7-9.~ ~Belli P (2003): Formal and informal
311   IV,    11.  6.  5    |               Health Care. 2002; 18(2), p 364.~ ~Carrin G, Hanvoravongchai
312   IV,    11.  6.  5    |               Carrin G, Hanvoravongchai P (2003): "Provider payments
313   IV,    11.  6.  5    |         Physician 67(4): 697.~ ~Durieux P, Chaix-Couturier C et al. (
314   IV,    11.  6.  5    |                Hall.~ ~Goddard M, Smith P (2001): "Equity of access
315   IV,    11.  6.  5    |             Health Economics.~ ~Kanavos P, Mossialos E (1999): "International
316   IV,    11.  6.  5    |                and Policies.~ ~Musgrove P (2003): "Judging health
317   IV,    11.  6.  5    |          performance in OECD countries. P. Smith. Paris, Organisation
318   IV,    11.  6.  5    |                  55-72.~ ~Rice N, Smith P (2002): Strategic resource
319   IV,    11.  6.  5    |                and development.~ ~Smith P, Ed. (2002): Measuring Up:
320   IV,    11.  6.  5    |                and Development.~ ~Smith P (2004): "Health care reforms
321   IV,    11.  6.  5    |               95.~ ~Sorenson C, Kanavos P et al. (2007): Ensuring
322   IV,    11.  6.  5    |            Approaches for New Outcomes. P. Cox.~ ~Spooner A, Chapple
323   IV,    11.  6.  5    |              2nd ed., 1998~ ~Vaughan, J.P., Morrow, R.H. Manual of
324   IV,    12.  1        |          Freedom,~Security Justice Data P rotecti on~ ~ ~Protection
325   IV,    13.  9        |             References~ ~Andlin-Sobocki P, Jönsson B, Wittchen HU,